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PECULIARITIES OF HEMODYNAMIC DISORDERS  
IN HYPERTENSIVE PATIENTS DEPENDING ON BODY WEIGHT  
AND METABOLIC COMORBIDITY 
 
Introduction. The problem of "non-infectious" epidemics is a burning issue in 
the world today. According to the WHO in 2018, non-communicable diseases 
(NCDs) dominant among the main reasons for the increase in morbidity and 
mortality in many countries in the XXI century. The main risk factors for NCDs 
globally are high blood pressure (BP) (over 18% of all cases), obesity, 
hyperglycemia and hyperlipidemia. Obese patients, even in the absence of diabetes 
mellitus (DM), hypertension (AH) and any other heart disease, develop 
hemodynamic changes leading to morphological and functional changes in the left 
ventricle (LV), even a small increase in arterial pressure (BP) causes a pronounced 
increase in its mass (LVM) [1, 2]. From a hemodynamic point of view, it is not clear 
why the thickening of the LV myocardial walls develops more rapidly and more 
pronounced in obesity than in isolated hypertension, why this combination often 
forms a concentric type of LV remodeling. One explanation may be that the 
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thickness of the LV walls in obesity increases not only in response to increased BP, 
but also as a side tissue reaction of the myocardium to hormonal and metabolic 
changes inherent in obesity [3, 4]. In recent years, a number of studies have been 
conducted that prove the mechanisms of lipotoxic damage to the myocardium in 
obesity, which changes both the structure of the myocardium and its functional state 
[5, 6]. The relationship between obesity and structural and functional changes in the 
heart, including LV hypertrophy, contractile dysfunction, apoptosis, cardiomyocyte 
fibrosis, has been shown. In conditions of combination of AH with obesity and 
diabetes, interstitial and perivascular fibrosis develops. Myocardial fibrosis leads to 
disorders of diastolic and systolic function and is associated with the development 
of adverse cardiovascular events [7-9]. The early stages of myocardial dysfunction 
are closely associated with the formation of diastolic disorders due to increased 
myocardial rigidity 
The aim was to study the features of hemodynamic disorders in hypertensive 
patients depending on body weight and metabolic comorbidity. 
Materials and Methods: We examined 340 patients with arterial 
hypertension: 200 patients with AH with class I - II obesity, 50 patients with AH 
and normal body weight, 50 patients with AH and overweight, 40 patients with AH, 
obesity and type 2 diabetes. The test group consisted of 30 healthy individuals. All 
patients aged 45-55. Anthropometric, biochemical, instrumental, statistical methods 
were used. 
Results: In the course of the study, it was concluded that the degree of disorders 
of the structural and functional state of the heart and blood vessels increases with 
the increase of the body weight both in case of double (AH with obesity) and triple 
(AH, obesity and type 2 diabetes) comorbidity. In the absence of significant 
differences between overweight and normal weight patients, patients with obesity 
had significantly higher CIMT, cPWV, and aPWV values (p <0.05 for all 
indicators). At the same time, the greatest severity of vascular remodeling was in 
patients with concomitant type 2 diabetes, which significantly distinguished this 
group from all the others, and the values of such indicators as CIMT, cPWV and 
aPWV - in particular, from hypertensive patients with obesity without type 2 
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diabetes (p <0.05 for all indicators). Patients with obesity had a significantly lower 
level of EDVD than patients with normal body weight and overweight. An increase 
in body weight from normal to grade II obesity in patients with AH is accompanied 
by decreases in EDVD, an increase in LVESD and LVM, an increase in LAD and 
LV wall thickness (p <0.05 for all indicators).  
The main indicator of cardiac systolic function - EF - in patients with obesity 
was lower compared with patients with normal body weight (62.99 ± 3.32 % vs 
64.42 ± 2.23 %, p = 0.004), despite the fact that only patients with preserved LVEF 
were included in the study. In the presence of obesity, the increase in pulmonary 
artery pressure according to Kitabatake distinguished this group from patients with 
normal body weight and overweight (p = 0.000 for both indicators), and the increase 
in integral diastolic function (E / e´) was significantly higher compared with 
hypertensive patients with normal body weight (p <0.05), which confirms the 
progression of diastolic dysfunction in the case of weight gain. 
In all groups of hypertensive patients most often diagnosed with a concentric 
type of remodeling with a predominance of concentric hypertrophy (AH + obesity 
- 71.5%, AH + normal BMI - 70%, AH + overweight - 62%, AH, obesity + type 2 
diabetes - 72, 5%) as a prognostically unfavorable type of remodeling in the 
absence of significant differences between groups with different body weight  
(p> 0.05). The incidence of the normal type of transmitral blood flow in 
hypertensive patients with obesity was significantly lower than in hypertensive 
patients with normal body weight (p = 0.019). The distribution of normal and 
impaired transmitral blood flow in the groups of hypertensive patients was 
approximately the same, in the vast majority of patients there was the first degree 
of diastolic dysfunction in the form of impaired relaxation (AH + obesity – 76.5 
%, AH + normal BMI – 60 %, AH + overweight – 76%, AH, obesity + type 2 
diabetes – 70%). Maximum disorders of the structural and functional state of the 
heart and blood vessels were found in the group of patients with triple comorbidity 
(p < 0.05 for all indicators), where 7.5 % of patients had a more severe, 
pseudonormal, type of LV diastolic dysfunction.  
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Conclusions: The peculiarities of the structural and functional state of the heart 
and blood vessels in patients with hypertension with different body weight and the 
role of weight gain and metabolic comorbidity in the development and progression 
of cardiovascular remodeling are determined.  
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